Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (March 2023)
42 slides from Corbus Pharmaceuticals's investor presentation, Mar 7, 2023
Slide 1: Connecting Innovation to Purpose: Corporate Presentation March 2023
Connecting Innovation to Purpose Corporate Presentation March 2023 NASDAQ: CRBP • CorbusPharma.com • @CorbusPharma Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Co
Slide 3: Introducing the new Corbus Pharmaceuticals
Introducing the new Corbus Pharmaceuticals Norwood, MA (Boston area) NASDAQ: CRBP Precision oncology + differentiated assets Established targets enhance probability of success Multiple catalysts in 2023 – 2024
Slide 4: A diversified pipeline with different risk profiles
Compound Indications Preclinical Phase 1 Phase 2 Phase 3 Next Generation Nectin-4 targeting ADC CRB-701 Next generation Nectin-4 targeting ADC Urothelial cancer Nectin-4 enriched solid tumors Anti-Integrin mAb CRB-601 Anti-⍺vβ8 mAb (TGFβ-targeting) ⍺vβ8 enriched solid tumors IND H2 2023 First Patien
Slide 5: CRB-701 Next Gen Nectin-4 Targeting ADC
CRB-701 Next Gen Nectin-4 Targeting ADC
Slide 6: Nectin-4 is a clinically validated target with untapped potential
Nectin-4 is a clinically validated target with untapped potential Cell adhesion molecule important in adherence junction formation Ligand of TIGIT, known to inhibit NK cell activity Tumor-associated antigen (TAA) with a restricted distribution in normal tissue and overexpression in multiple tumors S
Slide 7: PADCEV projected to reach up to ~$5B in global sales
PADCEV® projected to reach up to ~$5B in global sales by 2028 Late-stage Clinical Development Source(s): SeaGen website, Evaluate Ltd $5B 1Projected revenues for UC/Bladder only Indications Phase 1 Phase 2 Phase 3 Approved 2L+ Urothelial Cancer (UC) Monotherapy 1L Urothelial Cancer + pembrolizumab M
Slide 8: PADCEV safety limitations impact tolerability and dose intensity
PADCEV® safety limitations impact tolerability and dose intensity A Black Box warning for PADCEV ® cautions physicians regarding the skin toxicity risk1 PADCEV® monotherapy1 PADCEV® + pembrolizumab2 Skin Reactions 55% 67% Peripheral Neuropathy 52% 61% PADCEV® Adverse Events (% of patients) Source(s)
Slide 9: CRB-701: next generation site-specific Nectin-4 targeting ADC
CRB-701 CRB-701: next generation site-specific Nectin-4 targeting ADC CRB-701 Mechanism of CRB-701 ADC Selective binding of CRB-701 to Nectin-4 Internalization of CRB-701/Nectin-4 complex via endocytosis Intracellular cytosol release of MMAE (payload) due to lysosomal trafficking MMAE cytotoxic effe
Slide 10: CRB-701 is designed to be an improved Nectin-4 targeting ADC
CRB-701 is designed to be an improved Nectin-4 targeting ADC Novel antibody Comparable affinity and selectivity to the antibody in current SOC but proprietary CDRs. CRB-701 has ADCC / CDC functionality. Potential for retreatment in PADCEV® intolerant patients. Designed for improved therapeutic index
Slide 11: CRB-701 demonstrates potent monotherapy in diverse tumors
CRB-701 demonstrates potent monotherapy in diverse tumors Comparison of in-vivo pharmacology Prostate Cancer Triple Negative Breast Cancer P *** 0.001; ** 0.01; * 0.1 If improved therapeutic index is demonstrated clinically then the potential to see both a higher dose & greater efficacy exist ** **
Slide 12: CRB-701: preclinical data suggests a differentiated Nectin-4 targeting ADC
CRB-701: preclinical data suggests a differentiated Nectin-4 targeting ADC Longer half-life of the ADC and lower plasma concentration of payload Preferentially delivers payload to the tumor vs. plasma Better efficacy in Nectin-4 low expressing urothelial tumors Tumor Growth Inhibition (TGI) @ 3mg/kg
Slide 13: CRB-701: differentiated by immune-mediated tumor destruction functionality
CRB-701: differentiated by immune-mediated tumor destruction functionality The CRB-701 antibody has built-in Fc receptor binding activity innate immune mediated tumor destruction CRB-701 has demonstrated potency against FcγR1, C1q and FcRn This additional antibody functionality is designed to incr
Slide 14: CRB-701: designed for a differentiated product profile
CRB-701: designed for a differentiated product profile Feature CRB-701* PADCEV® BT8009 MOA ADC ADC BTC Clinical Stage Phase 1 (China) Approved Phase 2 Other functionality ADCC + CDC No ADCC or CDC No ADCC or CDC Payload release Internalization Internalization Can release without internalization Link
Slide 15: Urothelial cancer provides first clinical validation of Nectin-4 ADC
Urothelial cancer provides the first clinical validation of using a Nectin-4 targeting ADC PADCEV® in urothelial cancer 97% of patients were Nectin-4 positive2 290 avg H-score (range 14 - 300) 2 63% of samples had H-scores ≥ 100 in an independent study 524 patients2 PADCEV® monotherapy1 ORR 44% Comp
Slide 16: Response to Padcev could be tied to expression level of Nectin-4
Response to Padcev® could be tied to expression level of Nectin-4 Response to Padcev® in the EV-201 study expressed as a function of Nectin-4 expression (H-score)1 Source: 1. Multi-Discipline Review. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761137Orig1s0
Slide 17: CRB-701 differentiation + novel development strategy
CRB-701 differentiation + novel development strategy expansion beyond urothelial cancer CRB-701 Improved therapeutic Companion diagnostic Developing CDx is key to patient selection Indication validation Nonclinical validation of the Nectin-4 receptor will influence indication selection Limited com
Slide 18: Corbus data analysis points to specific tumors outside current competition
Corbus data analysis points to specific tumors outside current competition Source(s): Corbus proprietary analysis: Log2 fold change of nectin-4 expression as a ratio to normal tissue Differentiation of CRB-701’s approach Selecting tumors with a strong differential Nectin-4 gene expression Uncovering
Slide 19: CSPC: a top five biopharmaceutical company in China
CSPC: a top five biopharmaceutical company in China1 HKSE: 1093.HK Market Cap: $15.7B2 2021 Revenue: $4.1B2 # of employees: 23,000+ 864 drug licenses, 68 API licenses 1,363 patent applications among which 772 have been authorized ~300 R&D projects under development, ~100 innovative projects Recent U
Slide 20: CRB-701 collaboration will leverage CSPC capabilities
CRB-701 collaboration will leverage CSPC capabilities Translational work on MOA in solid tumors Companion diagnostic validation Clinical bridging study in US using China RP2D (2024) Phase 1b/2 in Nectin-4 enriched solid tumors Dose escalation (underway in China) Urothelial cancer clinical developmen
Slide 21: US activation of CRB-701 is planned in 2024
US activation of CRB-701 is planned in 2024 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 The Corbus development approach will consider: Clinical differentiation Translational validation Companion diagnostic development CRB-701 Development Timeline Non-clinical validation of Nectin
Slide 22: CRB-601 Potential best-in-class αvβ8 mAb
CRB-601 Potential “best-in-class” ⍺vβ8 mAb
Slide 23: CRB-601 has the potential to enhance checkpoint inhibition
CRB-601 has the potential to enhance checkpoint inhibition Focus on adopting a precision-targeted approach Novel mechanism to target TGFb in the tumor microenvironment Large opportunity potential if POC is validated
Slide 24: TGFβ plays a central role in immunoregulation and cancer
TGFβ TGFβ plays a central role in immunoregulation and cancer Source(s): Dahmani A, Delisle JS. TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. Cancers (Basel). 2018;10(6):194. Published 2018 Jun 11. doi:10.3390/cancers10060194 TGFβ has been associated with immune cell exclusion in c
Slide 25: TGFβ predicts poor clinical outcomes in a subset of cancer patients
TGFβ predicts poor clinical outcomes in a subset of cancer patients 0 25 20 15 10 5 0.0 0.2 0.4 0.6 0.8 1.0 N = 8,461 cancers, multiple cell types Time (years) Overall survival, % Immunogenomic subtypes in cancer Source(s): Thorsson, et al. The Immune Landscape of Cancer, Immunity. 2018; 48:817 C1 C
Slide 26: Targeting integrin αvβ8 is a novel approach to regulating TGFβ
Targeting the integrin ⍺vβ8 represents a novel approach to regulating TGFβ Source(s): Huang et al., 2021. Recent progress in TGFβ inhibitors for cancer therapy. Novel point of therapeutic intervention Blocking the ⍺vβ8 activation of TGFβ in the local tumor micro environment TGF-β Antibody Ligand Tra
Slide 27: Significant opportunity in improving response to PD-1/L1
Significant opportunity in improving response to PD-1 /L1’s 70 - 80% of patients do not respond to PD-1/L1 therapy1 $70B+ in projected PD-1/L1 sales worldwide by 20282 Opportunity to improve response with biomarker-based, precision combos Source(s): Sun, JY., Zhang, D., Wu, S. et al. Resistance to P
Slide 28: TGF-β signaling negatively associated with PD-L1 inhibitor responses
TGF-β signaling has a negative association with PD-L1 inhibitor responses clinically Anti PD-1 response in Urothelial cancer (68 responders / 230 non-responders) TGFb1 gene expression nonresponse p = 0.00011 OS (likelihood ratio test) p = 0.0096 Source(s): Mariathasan et al., 2018 Nature. 554(7693):
Slide 29: Renewed interest in TGFβ via new approaches to prevent activation
Renewed interest in TGFβ via new approaches to prevent activation Source(s): Company websites. Clinicaltrials.gov. Internall analysis. CRB-601 PF-06940434 SRK-181 ABBV-151 PLN-101095 TBD MOA ⍺vβ8 ⍺vβ8 L-TGFβ GARP (TGFβ1) ⍺vβ8/β1 ⍺vβ8 Clinical Stage IND in H2 2023 Phase 1 Phase 1 Phase 1 IND Preclini
Slide 30: CRB-601 enhances anti-PD-1 therapy in murine tumor models
CRB-601 enhances anti-PD-1 therapy in checkpoint inhibition sensitive and resistant murine tumor models CRB-601: 10 mg/kg BIW Anti-PD-1: 10 mg/kg BIW 10 animals / group Animals randomized at 50-80 mm3 Comparisons across arms *p<0.05, ***p<0.001, ****p<0.0001 % TGI MC38 EMT6 4T1 Anti-PD-1 54 -8 6 CRB
Slide 31: αvβ8 blockade with anti-PD-1 increased TIL populations in EMT6 tumors
Blockade of ⍺vβ8 in combination with anti-PD-1 increased TIL populations in immune excluded EMT6 tumors **** *** **** **** **** *** **** **** Ki67+CD4 T Cells Ki67+CD8 T Cells CD4 T Cells CD8 T Cells Tumor Size * *** * **** ** *** ** *** ** **** * **** * Treatment Days -14 0 3 6 10 Anti-PD-1, 10 mg/
Slide 32: αvβ8 expression levels relate to antitumor activity of CRB-601
Levels of αvβ8 expression on tumor cells are closely related to the antitumor activity of CRB-601 in the same syngeneic models. Corbus data demonstrates the value proposition of enriching patients for response CDx strategy for CRB-601 to increase probability of success Source(s): Corbus data on file
Slide 33: Applying a proprietary algorithm to define the clinical focus for CRB-601
Applying a proprietary algorithm to define the clinical focus for CRB-601 A multi-parametric, immune-focused algorithm has refined indications for CRB-601 The combination of immune features and gene expression profiles have identified 9 indications for clinical priority High Low Quartiles Source(s):
Slide 34: Patient selection strategies will enhance probability of success
Patient selection strategies will enhance the probability of success Source(s): Corbus proprietary analysis: Log2 fold change of nectin-4 expression as a ratio to normal tissue Controls Ovarian Melanoma Breast Colon Prioritization of indications with differential gene expression vs. normal tissues w
Slide 35: CRB-601 Next Steps
CRB-601 Next Steps IND filing scheduled for H2-2023 FPI expected before the end of 2023 Non-clinical validation of a potential patient selection biomarker in 2023 Dose escalation and confirmation will be the focus through 2024
Slide 36: Upcoming catalysts
Upcoming catalysts
Slide 37: 2023 - 2024 Catalysts
2023 - 2024 Catalysts 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 CRB - 601 ⍺vβ8 mAb CRB - 701 Nectin-4 targeting ADC FPI (China) RP2D (China) RP2D (US) US CDx partnership IND H2 2023 FPI AACR-NCI-EORTC ASCO Clin Pharm TGFβ Summit Trials in Progress AACR ESMO ASCO Trials in Progr
Slide 38: Leadership
Leadership
Slide 39: Management Team
Management Team Yuval Cohen, PhD Chief Executive Officer, Director Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005 Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014. P
Slide 40: Board of Directors
Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA Avery W. (Chip) Catlin Director More than 25 years of senior financial leadership experience in life science companies; Form
Slide 41: Investment Summary
Investment Summary Advancing anti-⍺vβ8 integrin program to IND submission in H2 2023 Engaging in business development activities to expand Corbus oncology pipeline Sufficient capital to fund operations through the second quarter of 2024 CRBP Ticker $59.2 Million Cash and investments as of December 3
Slide 42: Corbus Pharmaceuticals
CORBUS PHARMACEUTICALS
Corbus Pharmaceuticals Holdings — Investor Presentation (March 2023) on 6ix